a post|hoc analysis of the SELECT phase 3 trials

a post-hoc analysis of the SELECT phase 3 trials | Rheumatology ...

This post-hoc analysis from four phase 3 trials explored the efficacy of upadacitinib (UPA) for moderately active RA.

a post-hoc analysis of phase 3 trials and long-term extension

Background Evaluate the impact of sex on tofacitinib efficacy, safety and persistence (time to discontinuation) in patients with psoriatic arthritis (PsA).

a post hoc analysis of data from phase 3 trials of tofacitinib - PubMed

To support the main analysis, associations between select patient-reported outcomes (PROs) were also evaluated in csDMARD-naïve (ORAL Start; ...

a post hoc analysis of SELECT-PsA 1 and 2 trials | Rheumatology

To characterize the effect of upadacitinib 15 mg once daily (UPA15) on enthesitis in patients with PsA from the SELECT-PsA Phase 3 trials.

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

... SELECT-PsA 1 and 2 Phase 3 Trials. Rheumatol Ther. 2022 Aug;9(4):1181 ... This study looked at results from two clinical trials that ...

SELECT Trial: Post-Hoc Analysis - Targeted Oncology

Andrew Gianoukakis, MD, and Lori Wirth, MD, examine post-hoc analysis data from the phase 3 SELECT trial.

Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials

The aim of our work is to assess the prevalence of probable major depressive disorder and/or probable generalized anxiety disorder ...

AB1090 EFFICACY OF UPADACITINIB IN PATIENTS WITH ...

... A POST HOC SUBGROUP ANALYSIS OF THE PHASE 3, RANDOMIZED, SELECT-PSA 1 AND SELECT-PSA 2 TRIALS. Free. Loading. K. Mizelle1,; W. Tillett2,3,; M. Ali4,; T. Iyile4, ...

What is Post-Hoc Analysis in a Clinical Trial?

They must also carefully select the demographics of the people who will participate in the trial to make sure that they will be able to ...

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

The SELECT-CHOICE trial, a phase 3, double-blind trial involving patients with an inadequate response to biologic DMARDs, was designed to ...

Upadacitinib in Rheumatoid Arthritis and Inadequate Response to ...

... phase 3 trial. Lancet 2018;391:2513-24. OpenUrl ... post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.

Characterization of acne associated with upadacitinib treatment in ...

This was a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials of upadacitinib, alone (NCT03569293 and ...

Final analysis of survival outcomes in the phase 3 FIRST trial of up ...

The primary endpoint was progression-free survival (PFS; primary comparison: Rd continuous vs MPT). Overall survival (OS) was a key secondary endpoint (final ...

Long-term kidney outcomes of semaglutide in obesity and ... - Nature

In this pre-specified analysis of the SELECT trial, we found that ... hoc analysis of an open-label, randomised, phase 3 trial. Lancet ...

Achievement of Disease Control in PsA Patients Treated with ...

... phase 3 trials. Methods: Post hoc analysis of pts from the SELECT-PsA 1 (N=1704; inadequate response to non-biologic DMARDs [non-bDMARD-IR]) and SELECT-PsA ...

Semaglutide versus placebo in patients with heart failure and mildly ...

We conducted a post-hoc pooled, participant-level analysis of four randomised, placebo-controlled trials (SELECT, FLOW, STEP-HFpEF, and STEP ...

Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017 ...

Patients were randomized 1:1 to receive strategy A (first-line treatment with an NSAI + CDK4/6i, followed on progression by fulvestrant (F)) or strategy B ( ...

Semaglutide Effects on Cardiovascular Outcomes in People With ...

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.

Semaglutide and Cardiovascular Outcomes in Obesity without ...

(Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.) ... Table 3 provides a summary of the continuous and binary supportive secondary ...

Trial Design Semaglutide Effects on Cardiovascular Outcomes in ...

The GLP-1 RA semaglutide is in phase 3 studies as a medication for obesity ... SELECT will be the first clinical trial designed to explore the ...